Complement, a Therapeutic Target in Diabetic Kidney Disease

Frontiers in Medicine

Samuel Mon-Wei Yu¹  Sergio Dellepiane¹  Kelly Budge¹  Paolo Cravedi² 

[1] Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States;null;

关键词: diabetes;    diabetic kidney disease;    C3a;    complement;    glomerulosclerosis;    MAC;    C5a;   

DOI  :  10.3389/fmed.2020.599236

来源: Frontiers

【 摘 要 】

Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests complement activation in DKD. With existent drugs and clinical success of treating other kidney diseases, complement inhibition has emerged as a potential novel therapy to halt the progression of DKD. This article will review DKD, the complement system's role in diabetic and non-diabetic disease, and the potential benefits of complement targeting therapies especially for DKD patients.

【 授权许可】

CC BY